Trade Biogaia B - BIOGb CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.6
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investmentSEK 1,000.00Overnight funding adjustmentCharges from full value of position-0.015664 %(-SEK 0.80)Trade size with leverage ~ SEK 5,000.00Money from leverage ~SEK 4,000.00Go to platform: -0.01566%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investmentSEK 1,000.00Overnight funding adjustmentCharges from full value of position-0.006559 %(-SEK 0.30)Trade size with leverage ~ SEK 5,000.00Money from leverage ~SEK 4,000.00Go to platform: -0.00656%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: SEK
• Min traded quantity: 1
• Margin: 20.00%
• Stock exchange: Sweden
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: SEK 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.015664 %
  (-SEK 0.80)

• Margin. Your investment: SEK 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.006559 %
  (-SEK 0.30)

Key Stats

• Prev. Close: 116.1
• Open: 113.9
• 1-Year Change: 14.36%
• Day's Range: 113.9 - 116.4

Trade Biogaia B - BIOGb

About BioGaia AB

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioGaia AB revenues increased 5% to SEK785.1M. Net income increased 9% to SEK196.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Other operating expenses/operating incom decrease from SEK17.4M (expense) to SEK11.2M (income). Dividend per share increased from SEK6.82 to SEK7.26.